Researchers at Stanford have facilitated active agent passage across the blood-brain barrier (BBB) by conjugating the active agent with a plasma protein that gets taken up by microglia.
The BBB is a partitioning layer that regulates the passage of substances to protect the brain from potential harm. While its selective permeability is crucial for neural protection, it makes drug delivery to the brain extremely difficult, limiting treatment efficacy for various neurological or psychiatric conditions. It is important to enable the necessary therapeutics to traverse the BBB in order to ensure targeted and efficient delivery to the intended brain region.
Stanford researchers have discovered a brain drug delivery method that capitalizes on a natural transport mechanism. They identified and engineered a drug delivery platform based on a plasma protein called Apolipoprotein A1 (Apo1A1) that can inherently cross the BBB. The ApoA1-conjugated active therapeutic agent crossed the BBB successfully and was found in brain microglia in mice.
Figure 1. A) Experiment overview. B) Percentage of ApoA1+ microglia (MG) in 6 different brain regions (n = 4).
Stage of Development
In vivo data
- Brain drug delivery platform for:
- Neurodegenerative diseases
- Brain tumors
- Neurological infection
- Pain management
- Psychiatric disorders
- Leverages the natural uptake of plasma protein by microglia to cross the BBB
- No alteration of the BBB or immune system required
Improving the solubility and pharmacokinetic profile ofc an insoluble therapeuticS22-073
Improving the solubility and pharmacokinetic profile ofc an insoluble therapeutic
Exosomes from Postpartum Nursing Females as Therapy for Ischemic InjuryS22-069
Exosomes from Postpartum Nursing Females as Therapy for Ischemic Injury
Injectable shear-thinning and self-healing hydrogel networksS22-379
Injectable shear-thinning and self-healing hydrogel networks